3SOF

OSTE - Osteotech

Osteotech, Inc. develops technologies and products to efficiently and effectively utilize bone and bone connective tissue (allograft bone tissue). Utilizing its expertise in musculoskeletal tissue technology, Osteotech provides services, and develops, markets and sells products to the orthopedic, neurological, oral/maxillofacial and general surgery markets around the world. The Company s primary operation is engaged in the processing of allograft bone tissue used for transplantation. The Company has two primary operating segments: Demineralized Bone Matrix (DBM) and Base Allograft Bone Tissue (Base Tissue). The DBM segment engages in the processing and marketing of Grafton and private label DBMs. The Base Tissue segment primarily engages in the processing of mineralized weight-bearing allograft bone tissue, including the Company s Graftech Bio-Implant allograft bone tissue forms.

NEWS: On Feb. 8, Osteotech, a bone graft products maker, said the U.S. Food and Drug Administration approved its bone-polymer biocomposite Plexur, which can be used to fill bony voids of the pelvis and extremities.

Stock has been up since then, on strong volumes.

My ratings:
T/A: ++
Analysts: ++
P/E: +
Profitability: --
Risk factors: --

VDSI - see my post of yesterday - up another 5% today

VDSI - reported earnings yesterday, new high, good volume, ON FIRE?

Business Summary :  VASCO Data Security International, Inc. (VASCO) designs, develops, markets and supports open standards-based hardware and software security systems that manage and secure access to information assets. It designs, develops, markets and supports the Strong User Authentication products for e-business and e-commerce. Strong User Authentication is delivered via the Company s hardware and software Digipass security products, called Digipass devices, most of which incorporate an electronic signature capability, guarantee the integrity of electronic transactions and data transmissions. Some of the Digipass units are compliant with the Europay MasterCard Visa standard, and are compatible with MasterCard s and VISA s new smart cards. The backbone of the Company s product range is the VACMAN Controller. For user access control, the VACMAN Middleware products limit application access to designated Digipass users. In October 2006, the Company acquired Able N.V., which is based in Mechelen, Belgium.

SCORES

P/E: --
Profitability: ++
T/A: ++
Risk factors: --
Analyst reports: -

EARNINGS YESTERDAY
AP
Vasco Surges to New High on 4Q Earnings
Tuesday February 20, 3:57 pm ET 
Vasco Data Security Shares Surge to New 52-Week High on Strong 4th-Quarter Earnings

NEW YORK (AP) -- Shares of security software maker Vasco Data Security International Inc. soared Tuesday after the company posted fourth-quarter earnings that came in ahead of Wall Street expectations.

Net income for the quarter was $5.1 million, or 13 cents per share, up from $3 million, or 8 cents per share, in the fourth quarter of 2005. Fourth-quarter revenue was $25.2 million, up 44 percent from $17.5 million in the year-ago period.

Analysts expected earnings of 11 cents per share on $25.7 million in revenue, according to a Thomson Financial analyst poll.

Income for the full year was $12.6 million, or 33 cents per share, up from $7.7 million, or 21 cents per share, for 2005. Revenue for the year was $76.1 million, up from $54.6 million in the year-ago period.

"The results of the fourth quarter showed the increasing strength of our products and the leverage in our business model," said Jan Valcke, president and chief operating officer.

Avondale Partners analyst P. Sean Jackson, who has a "Market Perform" rating on the stock, said the business metrics were indicative of a company in a "strong growth phase."

Shares of Vasco, which have traded between $6.88 and $15.99 over the last 52 weeks, were up $3.41, or 22.5 percent, at $18.84 in afternoon trading on the Nasdaq. Earlier in the session shares set a new year-high of $18.71.

Very strong over the past few days on high volume. On fire?

In @ 3.10, out @3.75 yesterday.
Will look at buying again on a dip today.

This one is skyrocketing. Is there still a technical target?
I am still in...

Rita Medical gets FDA OK on resection device - see Reuters

Up 5% in pre-market.

Have a look at the LJPC charts.
Could be a nice ride for the coming days.

Hi Bob,
I also went in a little late at $2.89, but I am still holding. Earnings soon, and I am not sure whether to sell or to hold now.

Am in @$9.25, way too late I am afraid. 
Let's sit, relax and wait... 

The stock is currently up another 11% in pre-market!